Hims & Hers to Add Novo Nordisk’s Ozempic and Wegovy Semaglutide Doses
Hims & Hers will add Novo Nordisk’s Ozempic (0.5–2.4 mg semaglutide injections) and Wegovy (1.5–25 mg injections and tablets) to its US weight-loss platform this month. The company will cease marketing compounded GLP-1s, transitioning patients to FDA-approved therapies while reserving compounded options for clinically necessary cases.
1. Novo Nordisk Collaboration Expansion
Hims & Hers has entered into an agreement with Novo Nordisk to list branded Ozempic semaglutide injections (0.5 mg, 1 mg, 2 mg, 1.7 mg, 2.4 mg) and Wegovy injections and tablets (1.5 mg, 4 mg, 9 mg, 25 mg) on its US weight-loss platform later this month.
2. Weight-Loss Platform Alignment
By aligning its US model with its global offering, the company will offer a broad assortment of FDA-approved GLP-1 medications and halt advertising of compounded semaglutide, reflecting accelerated customer demand for branded therapies.
3. Patient Transition and Support
Existing patients will have the opportunity to transition to FDA-approved medications when clinically appropriate, with the platform continuing to provide direct provider access, personalized nutrition guidance and ongoing clinical check-ins.
4. Lawsuit Dismissal
Novo Nordisk has dismissed its lawsuit against Hims & Hers without prejudice, removing legal obstacles and solidifying the strategic partnership for obesity treatment distribution.